نتایج جستجو برای: aβ1

تعداد نتایج: 893  

Journal: :Alzheimers & Dementia 2023

Background Clinical implementation of novel blood-based biomarkers for Alzheimer’s disease (AD) will aid in accurate, less-invasive diagnosis. However, variation blood handling may affect the accuracy biomarker’s measurement. Establishing standardized operating procedures (SOPs) to mitigate these effects is essential implementing into clinical use. We aim provide an evidence-based SOP specific ...

Journal: :Journal of Alzheimer's disease : JAD 2013
Sylvie Slaets Nathalie Le Bastard Jean-Jacques Martin Kristel Sleegers Christine Van Broeckhoven Peter Paul De Deyn Sebastiaan Engelborghs

It is assumed that the concentration of amyloid-β1-40 (Aβ1-40) in cerebrospinal fluid (CSF) reflects the total amount of Aβ protein in the brain and thus allows a better interpretation of inter-individual differences in Aβ quantity than the Aβ1-42 concentration. In this study, Aβ1-40 was added to the existing CSF biomarker panel of Aβ1-42, total tau (T-tau), and phosphorylated tau (P-tau181P) i...

2017
Amane Tateno Takeshi Sakayori Woo Chan Kim Michihiko Koeda Shinichiro Kumita Hidenori Suzuki Yoshiro Okubo

INTRODUCTION The plasma concentration of beta-amyloid (Aβ) has been considered another biomarker of Alzheimer's disease and was reportedly associated with cortical Aβ accumulation. METHODS We analyzed 28 subjects with apolipoprotein E4 (ApoE4; E4 group) and 89 subjects without ApoE4 (non-E4 group) to determine the association between cortical Aβ accumulation by standard uptake value ratio wit...

2015
Liandong Zhao Ying Zhao Haijun Zhang

AIM The study reported here aimed to examine how stent-assisted angioplasty affects cognitive status and serum levels of amyloid betas (Aβs) 1-40 and 1-42 in patients with cerebral arterial stenosis. METHODS Patients with cerebral arterial stenosis were given stent-assisted angioplasty plus conventional treatment (stent-assisted angioplasty group) or conventional treatment alone (control grou...

2010
Mirko Bibl Hermann Esselmann Piotr Lewczuk Claudia Trenkwalder Markus Otto Johannes Kornhuber Jens Wiltfang Brit Mollenhauer

We studied the diagnostic value of CSF Aβ42/tau versus low Aβ1-42% and high Aβ1-40(ox)% levels for differential diagnosis of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), respectively. CSF of 45 patients with AD, 15 with DLB, 21 with Parkinson's disease dementia (PDD), and 40 nondemented disease controls (NDC) was analyzed by Aβ-SDS-PAGE/immunoblot and ELISAs (Aβ42 and tau). Aβ4...

2014
Jeremy H. Toyn Lorin A. Thompson Kimberley A. Lentz Jere E. Meredith Catherine R. Burton Sethu Sankaranararyanan Valerie Guss Tracey Hall Lawrence G. Iben Carol M. Krause Rudy Krause Xu-Alan Lin Maria Pierdomenico Craig Polson Alan S. Robertson R. Rex Denton James E. Grace John Morrison Joseph Raybon Xiaoliang Zhuo Kimberly Snow Ramesh Padmanabha Michele Agler Kim Esposito David Harden Margaret Prack Sam Varma Victoria Wong Yingjie Zhu Tatyana Zvyaga Samuel Gerritz Lawrence R. Marcin Mendi A. Higgins Jianliang Shi Cong Wei Joseph L. Cantone Dieter M. Drexler John E. Macor Richard E. Olson Michael K. Ahlijanian Charles F. Albright

Alzheimer's disease is the most prevalent cause of dementia and is associated with accumulation of amyloid-β peptide (Aβ), particularly the 42-amino acid Aβ1-42, in the brain. Aβ1-42 levels can be decreased by γ-secretase modulators (GSM), which are small molecules that modulate γ-secretase, an enzyme essential for Aβ production. BMS-869780 is a potent GSM that decreased Aβ1-42 and Aβ1-40 and i...

Journal: :Alzheimers & Dementia 2023

Background Abnormal amyloid-β (Aβ) deposition in the brain has been defined as earliest pathological change of Alzheimer disease (AD). We combined immunoprecipitation (IP) with MALDI-TOF MS to develop IP-MALDI-MS, which is an analytical technique for plasma Aβ. This previously revealed that APP669-711/Aβ1-42 ratio, Aβ1-40/Aβ1-42 and a combination these two biomarkers (a composite biomarker) hum...

2016
Karen E. Marshall Devkee M. Vadukul Liza Dahal Alina Theisen Milena W. Fowler Youssra Al-Hilaly Lenzie Ford György Kemenes Iain J. Day Kevin Staras Louise C. Serpell

Amyloid β1-42 (Aβ1-42) plays a central role in Alzheimer's disease. The link between structure, assembly and neuronal toxicity of this peptide is of major current interest but still poorly defined. Here, we explored this relationship by rationally designing a variant form of Aβ1-42 (vAβ1-42) differing in only two amino acids. Unlike Aβ1-42, we found that the variant does not self-assemble, nor ...

2017
Ellis Niemantsverdriet Julie Ottoy Charisse Somers Ellen De Roeck Hanne Struyfs Femke Soetewey Jeroen Verhaeghe Tobi Van den Bossche Sara Van Mossevelde Johan Goeman Peter Paul De Deyn Peter Mariën Jan Versijpt Kristel Sleegers Christine Van Broeckhoven Leonie Wyffels Adrien Albert Sarah Ceyssens Sigrid Stroobants Steven Staelens Maria Bjerke Sebastiaan Engelborghs

BACKGROUND Evidence suggests that the concordance between amyloid-PET and cerebrospinal fluid (CSF) amyloid-β (Aβ) increases when the CSF Aβ1-42/Aβ1-40 ratio is used as compared to CSF Aβ1-42 levels alone. OBJECTIVE In order to test this hypothesis, we set up a prospective longitudinal study comparing the concordance between different amyloid biomarkers for Alzheimer's disease (AD) in a clini...

2012
Pedro Pesini Virginia Pérez-Grijalba Inmaculada Monleón Mercè Boada Lluís Tárraga Pablo Martínez-Lage Itziar San-José Manuel Sarasa

The present study was aimed at assessing the capability of Aβ1-40 and Aβ1-42 levels in undiluted plasma (UP), diluted plasma (DP), and cell bound (CB) to distinguish between early stages of Alzheimer's disease (AD), amnesic mild cognitive impairment (MCI), and healthy control (HC). Four blood samples from each participant were collected during one month and the levels of Aβ1-40 and Aβ1-42 were ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید